title: [Sputum smear conversion during intensive TB treatment phase according to HIV status, in hospitalised patients in Togo].
abstract: METHODS
  We prospectively studied patients with pulmonary TB, with or without HIV-1 co-infection, from December 1, 2007 to December 1, 2008. Two groups of patients naive for TB and antiretroviral treatment (group A: 96 co-infected TB/HIV and group B: 171 TB infected but HIV negative) were selected randomly. The CD4 count was assessed according to HIV status, and all patients received RHEZ TB treatment for 2 months. Pulmonary smear was assessed at two weeks, four weeks, six weeks, and eight weeks.
  
  
  RESULTS
  Two hundred and sixty seven patients were treated (26.6% of admissions). The mean age was 34.62 ± 11 years and the sex ratio was 1.3. A proportion of 35.75% patients were HIV co-infected with a median CD4 count at 157 cells per millimeter cube. The sputum smear conversion was obtained for more than 87.5% of patients in group A and 24.56% in group B at two weeks; 94% of patients in group A and 61.83% in group B at four weeks; 100% of patients in group A and 87.33% in group B at six weeks, and 100% of patients in group A and 96.77% in group B at eight weeks. P<0.05 at six weeks.
  
  
  CONCLUSIONS
  HIV infected TB patients were more susceptible to treatment than TB/HIV infected patients in the first six weeks.
authors.affiliation: Service des maladies infectieuses et de pneumologie, CHU de Tokoin, BP 57, Lomé, Togo. majeste7@yahoo.fr
authors.forename: M I
authors.initials: MI
authors.lastname: Wateba
authors.forename: S A
authors.initials: SA
authors.lastname: Diop
authors.forename: M
authors.initials: M
authors.lastname: Salou
authors.forename: K
authors.initials: K
authors.lastname: Womitso
authors.forename: S
authors.initials: S
authors.lastname: Nichols
authors.forename: O
authors.initials: O
authors.lastname: Tidjani
mesh_terms: D000328:Adult; D000995:Antitubercular Agents / Q000627:therapeutic use; D018791:CD4 Lymphocyte Count; D004359:Drug Therapy, Combination; D004977:Ethambutol / Q000008:administration & dosage / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D015658:HIV Infections / Q000150:complications*; D015497:HIV-1; D006801:Humans; D007297:Inpatients; D007538:Isoniazid / Q000008:administration & dosage / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009169:Mycobacterium tuberculosis / Q000302:isolation & purification*; D011446:Prospective Studies; D011718:Pyrazinamide / Q000008:administration & dosage / Q000627:therapeutic use; D012494:Sampling Studies; D013183:Sputum / Q000382:microbiology*; D014037:Togo / Q000453:epidemiology; D014397:Tuberculosis, Pulmonary / Q000150:complications / Q000188:drug therapy / Q000382:microbiology*; D055815:Young Adult
chemical_list: D000995:Antitubercular Agents; D011718:Pyrazinamide; D004977:Ethambutol; D007538:Isoniazid